Commentary · 8 Jun 2026
Review articlePublished 14 Dec 2023
High-dose Ambroxol for Disease Modification and Prevention of Gba1-Related Parkinson Disease: From the Wrong Mouse to the Right Drosophila
1Department of Neurology, Gaucher Unit, Shaare Zedek Medical Center, Jerusalem, Israel; 2Department of Medicine, Agyany Pharmaceutics Ltd., Jerusalem, Israel; 3Department of Neurology and Movement Disorders Clinic, Shaare Zedek Medical Center, Jerusalem, Israel; 4Department of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; 5Department of Neuropathology, University of Rostock, Rostock, Germany; 6Department of Biomedicine and Cancer Research, Shmunis School of Biomedicine and Cancer Research, Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Israel
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
After early skepticism, the association between Gaucher Disease (GD), a rare genetic disease and Parkinson's Disease (PD), the second most common neurodegenerative disorders, is well established, but its underlying mechanisms is controversial: loss of function (haploinsufficiency) or gain of function. Both approaches are supported by apparent suitable animal models. The commentary discusses the failure of substrate reduction therapy and the unlikeliness of success using enzyme replacement therapy (the loss-of-function hypothesis), and predicts future success for pharmacological chaperones, targeting the misfolded mutant glucocerebrosidase for GBA1-related PD (the gain-of-function mechanism). A unique clinical trial (AGPI) is presented, exclusively enrolling GBA1 carriers, focusing on high-dose Ambroxol in early-stage PD for both prevention and disease modification, with the hope to transform the management of GBA1-PD and related disorders.
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Alzheimers Disease & Parkinsonism.
Perspective · 8 Jun 2026
Oxidative Stress and Its Role in Neuronal Degeneration: Mechanisms and Implications
Commentary · 8 Jun 2026
Understanding the Pathophysiology of Prion-Induced Dementia
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Alzheimers Disease & Parkinsonism
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Majdolen Istaiti”
- BylineArticles whose byline prints “Michal Becker-Cohen”
- BylineArticles whose byline prints “Gilad Yahalom”
- BylineArticles whose byline prints “Shoshana Revel-Vilk”
- BylineArticles whose byline prints “Arndt Rolfs”
- BylineArticles whose byline prints “Mia Horowitz”
- BylineArticles whose byline prints “Ari Zimran”